Ultragenyx Pharmaceutical (RARE) Enterprise Value (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Enterprise Value data on file, last reported at -$406.0 million in Q1 2026.

• On a quarterly basis, Enterprise Value rose 16.7% year-over-year to -$406.0 million in Q1 2026; TTM through Mar 2026 was -$406.0 million, a 16.7% increase from a year earlier, with the FY2025 full-year figure at -$673.0 million, down 11.61% from the prior year.
• Enterprise Value for Q1 2026 stood at -$406.0 million, up from -$673.0 million in the prior quarter.
• Over the last five years, Enterprise Value for RARE reached as high as -$135.8 million in Q4 2022 and fell as low as -$888.7 million in Q3 2022.
• Historically, Enterprise Value has averaged -$521.5 million across 5 years, with a median of -$542.8 million in 2022.
• Across the five-year window, Enterprise Value jumped 58.37% in 2022 and plunged 177.62% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$135.8 million in 2022, then sank by 60.0% to -$217.2 million in 2023, then plunged by 177.62% to -$603.0 million in 2024, then dropped by 11.61% to -$673.0 million in 2025, then jumped by 39.67% to -$406.0 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$406.0 million in Q1 2026, -$673.0 million in Q4 2025, and -$418.2 million in Q3 2025.